SunTrust Banks lowered shares of Healthequity (NASDAQ:HQY) from a buy rating to a hold rating in a research report released on Thursday, MarketBeat Ratings reports. They currently have $90.00 price target on the stock, down from their previous price target of $105.00.
A number of other equities research analysts also recently issued reports on HQY. Raymond James lifted their price target on shares of Healthequity from $85.00 to $105.00 and gave the company an outperform rating in a research report on Monday, September 10th. Bank of America downgraded shares of Healthequity from a buy rating to a neutral rating and lifted their price target for the company from $84.00 to $105.00 in a research report on Thursday, September 6th. They noted that the move was a valuation call. BidaskClub upgraded shares of Healthequity from a buy rating to a strong-buy rating in a research report on Thursday, November 1st. Cantor Fitzgerald lifted their price target on shares of Healthequity from $68.00 to $80.00 and gave the company a neutral rating in a research report on Wednesday, September 5th. Finally, Citigroup reiterated a buy rating and set a $110.00 price target on shares of Healthequity in a research report on Wednesday, September 5th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $90.92.
HQY traded down $3.76 during trading on Thursday, reaching $70.27. The company’s stock had a trading volume of 44,005 shares, compared to its average volume of 672,181. Healthequity has a 52-week low of $42.92 and a 52-week high of $101.58. The firm has a market capitalization of $5.19 billion, a PE ratio of 130.28, a P/E/G ratio of 2.90 and a beta of 1.37.
Healthequity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, December 4th. The company reported $0.22 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.02. Healthequity had a return on equity of 12.42% and a net margin of 24.52%. The company had revenue of $70.50 million for the quarter, compared to analyst estimates of $69.60 million. During the same quarter in the previous year, the company earned $0.17 EPS. The firm’s revenue for the quarter was up 24.1% compared to the same quarter last year. On average, equities analysts predict that Healthequity will post 0.87 EPS for the current fiscal year.
In related news, VP Darcy G. Mott sold 4,000 shares of Healthequity stock in a transaction that occurred on Monday, October 22nd. The stock was sold at an average price of $87.01, for a total transaction of $348,040.00. Following the completion of the transaction, the vice president now directly owns 92,500 shares in the company, valued at approximately $8,048,425. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 12,000 shares of company stock valued at $1,027,400 over the last 90 days. Insiders own 4.00% of the company’s stock.
Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in shares of Healthequity by 11.3% during the 2nd quarter. BlackRock Inc. now owns 7,688,768 shares of the company’s stock worth $577,427,000 after purchasing an additional 777,915 shares during the last quarter. Morgan Stanley raised its holdings in Healthequity by 15.5% in the 3rd quarter. Morgan Stanley now owns 4,001,425 shares of the company’s stock valued at $377,775,000 after acquiring an additional 536,366 shares during the last quarter. FMR LLC raised its holdings in Healthequity by 2.3% in the 3rd quarter. FMR LLC now owns 3,488,107 shares of the company’s stock valued at $329,312,000 after acquiring an additional 77,565 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Healthequity by 24.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 872,322 shares of the company’s stock valued at $82,357,000 after acquiring an additional 169,985 shares during the last quarter. Finally, Carillon Tower Advisers Inc. raised its holdings in Healthequity by 751.9% in the 2nd quarter. Carillon Tower Advisers Inc. now owns 752,482 shares of the company’s stock valued at $56,511,000 after acquiring an additional 664,157 shares during the last quarter. Hedge funds and other institutional investors own 93.01% of the company’s stock.
Healthequity Company Profile
HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Recommended Story: How accurate is the Rule of 72?
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.